November 18, 2026
Health news, explained with evidence
LIVE

Two-Year Data Shows Sustained Benefit from Neuroimmune Modulation for Rheumatoid Arthritis

🔬 Research 2 min read 👁 6

A new 24-month study presented at the American College of Rheumatology annual meeting highlights the long-term efficacy of neuroimmune modulation therapy using an implantable vagus nerve stimulation device for rheumatoid arthritis patients.

Two-Year Data Shows Sustained Benefit from Neuroimmune Modulation for Rheumatoid Arthritis🔬Research

Photo: Medical Xpress

Key points

  • 24-month trial data presented at the American College of Rheumatology.
  • Implantable vagus nerve device used for rheumatoid arthritis patients.
  • Over 90 percent of participants continued therapy at two years.

A randomized pivotal trial evaluating neuroimmune modulation therapy has reported sustained clinical responses at 24 months for individuals suffering from rheumatoid arthritis. The findings were presented by Dr. John Tesser and colleagues at the annual meeting of the American College of Rheumatology, which took place from November 6 to 11 in Orlando, Florida. The study focused on patients who previously showed an inadequate response or intolerance to at least one biological or targeted synthetic disease-modifying antirheumatic drug.

The trial involved 242 participants across 41 study sites who received an implantable device designed to deliver a one-minute daily electrical stimulation to the left cervical vagus nerve. According to the data, 92.1% of patients maintained the stimulation therapy through the 24-month follow-up period, while 62.8% did not require the addition of conventional biological or targeted synthetic drugs. Researchers observed that the proportion of patients achieving specific improvement benchmarks—known as ACR20, ACR50, and ACR70 rates—progressed over time among those receiving only the stimulation therapy. Furthermore, low disease activity or complete remission was achieved by over half of the evaluated participants.

Coauthor Dr. David Chernoff of SetPoint Medical noted that these outcomes help validate vagus-mediated neuroimmune modulation as an alternative therapeutic approach for managing the condition. While these results suggest promising long-term prospects for device-based treatments, patients should consult their healthcare providers before making any personal medical decisions regarding therapy changes.

What to know:

  • Therapy type: Implantable device delivering daily electrical stimulation to the vagus nerve.
  • Study duration: 24-month follow-up data from a randomized trial.
  • Key metric: Over 70% achieved ACR20 improvement at 24 months without additional biologic drugs.

Source Medical Xpress — medicalxpress.com/news/2026-11-sustained-clinical-responses-neuroimmune… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.